Location History:
- Herzelia, IL (1991)
- Hertzlyia, IL (1994 - 2000)
Company Filing History:
4 out of 65 
3 out of 894 
1 out of 25 Years Active: 1991-2000
Title: The Innovative Mind of Yoel Kloog
Introduction
Yoel Kloog, based in Hertzliya, Israel, is an accomplished inventor known for his significant contributions to the field of neuropharmaceuticals. With a portfolio of four patents, Kloog has made remarkable advancements in the understanding and treatment of neurotoxicity and degenerative diseases.
Latest Patents
Kloog's latest patent focuses on Dexanabinol derivatives and their use as neuroprotective pharmaceuticals. This innovative work describes NMDA-blocking pharmaceuticals that utilize the stereospecific (+) enantiomer with a (3S,4S) configuration of delta-6-tetrahydrocannabinol type compounds. The compositions are noteworthy for their ability to prevent neurotoxicity caused by acute central nervous system injuries, such as mechanical trauma, cardiac arrest, or stroke. Furthermore, they exhibit effectiveness in treating chronic degenerative diseases characterized by gradual neuronal loss, showcasing Kloog's commitment to enhancing neurological health.
Career Highlights
Throughout his career, Yoel Kloog has collaborated with esteemed organizations such as the Ramot University Authority for Applied Research and the Yissum Research Development Company of the Hebrew University of Jerusalem Ltd. These institutions have been instrumental in fostering his research, allowing him to explore innovative solutions in the pharmaceutical domain.
Collaborations
In his quest for innovation, Kloog has worked alongside notable colleagues, including Mordechai Sokolovsky and Raphael Mechoulam. Their collaborative efforts have significantly contributed to the advancement of knowledge in neuroprotective treatments and derivatives of cannabinoid compounds.
Conclusion
Yoel Kloog's journey as an inventor reflects a strong dedication to improving neurological health through his innovative research and patented technologies. His work not only provides groundbreaking solutions for preventing neurotoxicity but also illustrates the potential of cannabinoid derivatives in treating a range of degenerative diseases. As he continues to push the boundaries of science, Kloog stands as a notable figure in the field of neuropharmaceuticals.